Children don’t just bounce back after COVID.
A Bavarian study shows deep neurocognitive and emotional impacts in kids & teens - fatigue, loss of motivation, attention problems, mood disorders.
What they found🧵
85 children, ages 2-17 (avg 12.5, 61% girls). All had confirmed COVID and symptoms lasting ≥4 weeks.
They underwent multidisciplinary exams - psychiatry, neurology, cardiology, pulmonology, gastro + neuropsychological testing.
Most common symptoms.
fatigue (82%)
loss of motivation (73%)
attention/concentration problems (72%)!
low mood (53%)
anxiety (32%)
post-exertional malaise (70%)!
Not just stress.
Psychiatric findings.
83.5% had abnormal exams!
Most common diagnoses -
post-COVID adjustment disorder (39%)
post-COVID attention disorder (24%)
Over half required further psychiatric care!
Neuropsychological testing.
Main deficit - sustained attention (slower, more errors).
Working memory mostly normal, but 12% below average.
Well match sub study (50 kids, ages 3-12) showed worse scores vs healthy controls in verbal-logical thinking, attention & working memory (Wechsler test).
The authors present it as part of their results to demonstrate that even when using a standardized intelligence test, significant cognitive deficits become apparent.
Importantly - JAMA data show Long COVID affects even the youngest (ages 0–6).
They cannot describe brain fog or fatigue - but parents and teachers see it in sleep disruption, behavioral change, developmental delay.
Multiple studies now confirm rising psychiatric and cognitive impacts in children after COVID.
This is not limited to vulnerable groups. The biological impact of infection on the developing brain is broad and systemic!
Rates of psychiatric morbidity in post-COVID kids far exceed both the general population and the pandemic effect seen in COPSY data.
The infection itself is the driver - not just lockdowns or stress.
Sum:
COVID-19 can cause serious, lasting neurocognitive and emotional harm in children, disrupting school, relationships, daily life.
We must recognize this reality and build multidisciplinary care around it. @szupraha @ZdravkoOnline
Hauke-Gleisner at al. Neurocognitive and emotional long-term effects of COVID-19 infections in children and adolescents: results from a clinical survey in Bavaria, Germany. bmcinfectdis.biomedcentral.com/articles/10.11…
Follow-up clarification.
The Bavarian study shows what children referred for post-COVID symptoms look like. But it’s a next clinical cohort - results cannot be generalized to the whole population. So these findings do not establish prevalence.
Prevalence of pediatric LC remains uncertain - partly because there are still too few high-quality studies, and existing estimates vary widely (JAMA US vs European cohorts, different definitions, different methods).
But importantly - biological impacts of COVID in children are not simple on/off.
They exist on a spectrum, from mild transient changes to severe long-term dysfunction.
Prevalence estimates of pediatric Long COVID differ, depending on study & def.
6.3% US kids ever diagnosed w/ PCC - higher than asthma 5.8%. JAMA Pediatr 2025
1.3% ever PCC, 0.4% current symptoms
JAMA Pediatr 2024
2-10% in European cohorts
BMJ 2022. Lancet Child Adolesc Health 2022
So numbers vary - but the signal is clear - not rare, not fringe.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
SARS-CoV-2 can turn our own defenders into traitors.
A study in Sci Transl Med, 2025 shows the virus drives neutrophils into PMN-MDSCs cells that don’t fight, but suppress T cells.🧵
Instead of attacking the virus, these neutrophils hit the brakes on adaptive immunity.
T cells divide less, signal less.
The immune response collapses from within - right when it should be gaining strength.
And this is not just correlation.
Simply exposing neutrophils to SARS-CoV-2 in vitro was enough to reprogram them.
Contact with viral particles or proteins alone triggered the shift into PMN-MDSCs.
The virus can actively manipulate immunity from the start - not just passively ride the inflammation.
New study: SARS-CoV-2 doesn’t just lower white cell counts - it reshapes the T-cell landscape. Both the numbers and the quality of T-cells drop, especially in older and severely ill patients. And this has consequences. 🧵
Acute COVID-19 = a blow to T-cells. Patients had markedly lower absolute numbers of T-lymphocytes (CD4+, CD8+, naive and memory) compared to healthy controls. Classic lymphopenia - COVID cuts into the immune arsenal from the start. The immune system starts the fight with half its arsenal already gone.
Severity mirrors depth of the crash. The sickest patients had the lowest lymphocyte counts, especially CD8+ and naive T-cells. The steeper the disease, the deeper the T-cell depletion.
What wakes up Epstein-Barr virus (EBV) in Long COVID?
Most of us carry EBV silently for life.
But in Long COVID, EBV often wakes up - fatigue, brain fog, immune disruption.
Why? A new study just tested the main suspects🧵
The authors looked at 3 possibilities:
direct effect of SARS-CoV-2 on EBV+ cells
indirect effect via inflammation from infected cells
metabolic changes (esp heme)
Direct effect.
They infected EBV+ epithelial cells with SARS-CoV-2.
Result - the coronavirus replicates, but EBV stays asleep.
Interpretation - SARS-CoV-2 alone does not wake EBV.
Imagine a school year where 4 out of 5 students and staff get sick with a respiratory infection.
That’s not a dystopia.
That’s what a new study just found in a large US school district.🧵
816 children and staff were followed from November 2022 to May 2023.
They self-collected nasal swabs, reported symptoms, and were tracked week after week.
Result.
85% had at least one virus detected
80% had at least one acute respiratory illness (ARI)
(sic!)
New mega–meta-analysis on #LongCOVID ever prevalence.
Long COVID has affected 36% of people after a COVID-19 infection worldwide.
South America: 51%
Europe: 39%
Asia: 35%
USA: 29%🧵
Important note.
This 36% is “ever prevalence” - the share of people who at any point during follow-up had symptoms lasting ≥2 months after infection.
It does not mean they all still have symptoms today. Current prevalence is lower (eg 9% of US adults).
Why 2 months?
Different studies used different definitions of long COVID (WHO = 3 months, NASEM = 3 months, others = 2 months). To include the widest possible dataset, this meta-analysis defined long COVID as ≥1 new or persistent symptom lasting ≥2 months after infection.
A new Dutch study in BMJ Open 2025 followed people 2 years after COVID-19.
Even among those never hospitalized, 43% still had persistent symptoms.
This is a massive population-level impact.🧵
Hospitalized patients had higher prevalence of post-COVID (65%).
But they are a fraction of all infections.
The real burden comes from the huge group of mild cases!
The CORFU study = Corona Follow Up.
4,200 participants, 7 patient cohorts + controls.
Follow up at 3, 6, 12, 18, and 24 months.